Impact of the Coronavirus Disease Pandemic on Health-Related Quality of Life of Patients with Inflammatory Bowel Disease
Autor: | Annemarie C. de Vries, Rachel L A van Eijk, Annelieke Pasma, Nicole S. Erler, C. Janneke van der Woude, Emma Paulides |
---|---|
Přispěvatelé: | Gastroenterology & Hepatology, Rheumatology, Epidemiology |
Jazyk: | angličtina |
Rok vydání: | 2022 |
Předmět: |
Quality of life
medicine.medical_specialty Physiology Disease medicine.disease_cause Inflammatory bowel disease 03 medical and health sciences 0302 clinical medicine Disease control Surveys and Questionnaires Internal medicine Pandemic medicine Humans Pandemics Fatigue Coronavirus Response rate (survey) business.industry Gastroenterology COVID-19 Hepatology Inflammatory Bowel Diseases medicine.disease digestive system diseases 030220 oncology & carcinogenesis Chronic Disease Communicable Disease Control Original Article 030211 gastroenterology & hepatology business |
Zdroj: | Digestive Diseases and Sciences Digestive Diseases and Sciences, 67(7), 2849-2856. Springer New York |
ISSN: | 1573-2568 0163-2116 |
Popis: | Background To learn from the crisis caused by the coronavirus disease (COVID-19) pandemic and be prepared for future pandemics, it is important to investigate the impact of this period on the wellbeing of patients with inflammatory bowel disease (IBD). Aims To describe the health-related quality of life (HRQoL) and disease control of IBD patients during the first wave of the COVID-19 pandemic in The Netherlands. Methods Between March 17 and July 1, 2020, patients aged 18 years and older with IBD from the Erasmus MC (Rotterdam, The Netherlands) were invited to complete online questionnaires at week 0, 2, 6 and 12. The Inflammatory Bowel Disease Questionnaire (IBDQ), the Inflammatory Bowel Disease Control-8 (IBD-control-8) and the numeric rating scale on fatigue were used. The evolution of the different outcomes over time was measured using mixed models. Results Of 1151 invited patients, 851 patients (67% CD and 33% UC or IBD-U) participated in the study (response rate 74%). No relevant changes in total scores were found over time for the IBDQ (effect estimate 0.006, 95% CI [− 0.003 to 0.015]) and IBD-control-8 (effect estimate 0.004, 95% CI [0.998–1.011]). There was a slight, increasing trend in fatigue scores over time (effect estimate 0.011, 95% CI [0.004, 0.019]). Conclusions This first lock down due to the COVID-19 pandemic in The Netherlands did not impact on the HRQoL and disease control of patients with IBD. Up to date information may have contributed to a stable HRQoL in IBD patients even in an extreme period with restrictions and insecurities. Supplementary Information The online version contains supplementary material available at 10.1007/s10620-021-07118-8. |
Databáze: | OpenAIRE |
Externí odkaz: |